Medpace (MEDP) Q2 2026 earnings review
Bookings Rebound Alleviates Panic, Guidance Lifted
Medpace delivered a much-needed sigh of relief in Q2. After a disastrous Q1 plagued by record cancellations and a 0.88x book-to-bill, net new business awards surged 28% YoY to $795.7 million, pushing the ratio back to a healthy 1.13x. Revenue grew 17% to $707.3 million, and management capitalized on recent stock weakness by executing nearly $295 million in share buybacks. The solid execution allowed them to raise FY26 revenue and earnings guidance, signaling that the Q1 cancellation spike was an anomaly rather than a broken model.
🐂 Bull Case
The massive 28% YoY surge in net new business awards proves the 'pre-backlog' strength management touted last quarter is real and converting. The 1.13x book-to-bill firmly closes the book on Q1's cancellation fears.
Management increased the midpoint of their FY26 revenue outlook by $40 million and EBITDA by $10 million, showcasing strong visibility into the back half of the year.
🐻 Bear Case
Revenue growth has steadily stepped down from 32% YoY in late 2025 to just 17.2% today, pressured by tough comps and the normalization of high-pass-through metabolic studies.
With an incredibly high 24.1% conversion rate, Medpace burns through backlog fast. Total backlog grew just 4.9% YoY—a severe lag compared to the 17% revenue growth, demanding flawless bookings execution going forward.
⚖️ Verdict: 🟢
Bullish. The primary bear thesis from Q1—that cancellations were structural and demand was cracking—has been cleanly refuted by a strong bookings recovery, raised guidance, and aggressive buybacks.
Key Themes
Bookings and Net Awards Reversing the Panic
Reversing the disastrous 0.88x book-to-bill from Q1, Q2 bookings hit $795.7 million (+28.2% YoY). This confirms management's prior claim that underlying RFP flows were strong and the previous quarter's cancellations were isolated anomalies, likely tied to specific oncology or cardiovascular compound failures rather than systemic funding evaporation.
Aggressive Capital Returns Accelerating
After completely pausing repurchases in Q4 2025 and Q1 2026, management aggressively re-entered the market, buying back 705,616 shares for $294.7 million. This opportunistic deployment of capital signals immense internal confidence in the revised, higher FY26 guidance.
Margin Execution Remains Stable
Despite the sharp deceleration in top-line growth, EBITDA margins held perfectly stable at 21.7% (vs 21.6% a year ago). Medpace continues to extract operational leverage from its workforce, maintaining profitability even as the mix of highly-reimbursable (and margin-dilutive) metabolic studies fluctuates.
Top-Line Revenue is Decelerating
Decelerating aggressively. Revenue growth dropped to 17.2% YoY, down from 26.5% in Q1 and a peak of 32.0% in Q4. This slowdown is mathematically inevitable as the explosive COVID/post-COVID pipeline and massive GLP-1 pass-through costs normalize, but it caps top-line upside.
Backlog Growth Contradicts Booking Optimism
Stable but dangerous. Despite the celebrated bookings beat, ending backlog grew an anemic 4.9% YoY to $3.01 billion. This metric directly contradicts the hyper-bullish narrative: Medpace is churning through business with a 24.1% conversion rate. When revenue grows at 17% and backlog grows at 5%, the cushion shrinks rapidly, exposing the company to acute risk if gross awards stumble even for a single quarter.
Macro: Biotech M&A Threatens Core Base
A persistent macro risk remains for Medpace's specific business model: large pharma acquiring mid-cap biotech clients. As management previously acknowledged, when their biotech clients are acquired, they structurally lose future work. In a high-interest-rate environment where consolidation is a survival mechanism for biotechs, this creates a quiet, constant headwind.
Measured AI Implementation for Feasibility
Unlike competitors pitching tech overhauls, Medpace is taking a strictly measured approach to AI. They are currently rolling out AI-enabled applications specifically for data analytics in feasibility and site selection. However, management remains adamant that these tools will not provide a net financial benefit in the near term, keeping expectations grounded.
Other KPIs
Accelerating YoY. EBITDA grew 17.6% YoY, perfectly pacing revenue growth to deliver a 21.7% margin. This proves the company can defend its profitability regardless of the shifting therapeutic mix.
Strong cash generation continues to be a hallmark, funneling directly into the $294.7M buyback. Total cash sits at a robust $502.7M, giving management ample dry powder.
Guidance
Accelerating vs prior guidance. Management raised the full-year outlook from the initial $2.755 - $2.855 billion range set in Q4. The new midpoint ($2.845B) implies 12.4% YoY growth over FY25's $2.53 billion.
Accelerating. Lifted from the previous $605 - $635 million range. The midpoint of $630M implies ~13% YoY growth, slightly outpacing revenue growth and highlighting expected margin stability.
Accelerating. Upgraded from the prior $487 - $511 million forecast. The midpoint implies nearly 12% YoY growth, directly benefiting from the reduced share count following this quarter's massive buybacks.
Key Questions
Cancellations and the Pipeline
Did the Q1 cancellations permanently leave the pipeline, or did any of those delayed projects get re-awarded and contribute to the Q2 bookings surge?
Backlog Exhaustion
With backlog growing at just 4.9% while the conversion rate hits 24.1%, at what point does the lack of absolute backlog growth force a downward revision in 2027 revenue expectations?
Pace of Buybacks
After a massive $294.7M buyback in a single quarter, what is the strategy for the remaining $527M authorization? Will the aggressive cadence continue, or was this purely opportunistic based on the post-Q1 stock price drop?